JNX Stock Overview
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Therma Bright Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0025 |
| 52 Week High | CA$0.051 |
| 52 Week Low | CA$0.0025 |
| Beta | 2.99 |
| 1 Month Change | -54.55% |
| 3 Month Change | n/a |
| 1 Year Change | -93.06% |
| 3 Year Change | -99.16% |
| 5 Year Change | -83.33% |
| Change since IPO | -98.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| JNX | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -54.5% | -4.7% | -1.7% |
| 1Y | -93.1% | -11.0% | -0.2% |
Return vs Industry: JNX underperformed the German Medical Equipment industry which returned -9% over the past year.
Return vs Market: JNX underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| JNX volatility | |
|---|---|
| JNX Average Weekly Movement | 50.7% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: JNX's share price has been volatile over the past 3 months.
Volatility Over Time: JNX's weekly volatility has decreased from 57% to 51% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Rob Fia | www.thermabright.com |
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company’s products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients.
Therma Bright Inc. Fundamentals Summary
| JNX fundamental statistics | |
|---|---|
| Market cap | €2.16m |
| Earnings (TTM) | -€1.96m |
| Revenue (TTM) | €17.61k |
122.5x
P/S Ratio-1.1x
P/E RatioIs JNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNX income statement (TTM) | |
|---|---|
| Revenue | CA$25.79k |
| Cost of Revenue | CA$399.00 |
| Gross Profit | CA$25.39k |
| Other Expenses | CA$2.90m |
| Earnings | -CA$2.88m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0091 |
| Gross Margin | 98.45% |
| Net Profit Margin | -11,156.79% |
| Debt/Equity Ratio | 2.2% |
How did JNX perform over the long term?
See historical performance and comparison